When people living with HIV are admitted to a hospital, they may not be able to bring their medications with them, and could be prescribed new medication by a doctor who doesn't understand their complete medical history.
Two models, one from Washington State and another from Los Angeles County, can be duplicated elsewhere to get people into care, experts say.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
The data also reveals an estimated 2.3 million people living with HCV infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Prior studies have indicated that hepatitis C direct-acting antivirals reduce the risk of hepatocellular carcinoma, but this is the first large prospective study to compare outcomes among treated and untreated patients.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.
Several new HIV/HCV coinfection resources for the HIV workforce were recently released by partners of the U.S. Department of Health and Human Services. Here's the department's quick roundup.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.